ClinicalTrials.gg
CompletedNCT01096966Updated Jun 15, 2022

Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

A Phase 2 interventional study of Bupivacaine TTS (Bupivacaine Patch) and Placebo patch in Chronic Low Back Pain, sponsored by Durect. Completed at 21 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 711 studies in Low Back Pain with a site in United States — 99 open to participants now, 125 under way, 3 of them phase 3. Low Back Pain · United States.

Enrollment
107th of 623
263 · median 79
Started
2010
with 20 others
Phase 2
59 of 711
7 open now
Registered
147th of 711
by date

Among the 711 studies in Low Back Pain with a site in United States, this one is the 107th largest by enrollment of the 623 interventional ones that give a count, is one of 21 that started in 2010, is one of 59 in phase 2, and was the 147th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

99 of the 711 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 711 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of Bupivacaine TTS (Bupivacaine patch) compared to placebo in patients with chronic low back pain.

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

Keywords

  • chronic low back pain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of chronic low back pain for more than 3 months
  2. If taking non-steroidal anti-inflammatory drugs or non-opioid analgesics, must be on a regular, scheduled dose for at least 4 weeks prior to the first visit and intend to remain on a stable dose of these agents for the study duration
  3. Pain intensity score greater than or equal to 5 out of 10 at the first visit
  4. Able to apply patches at home
  5. Able and willing to complete daily pain intensity ratings using an electronic diary device for the duration of the study
  6. Females of must agree to use a medically acceptable method of throughout the study

Exclusion criteria

Exclusion Criteria:

  1. History of, or ongoing, alcohol or drug abuse
  2. Positive drug test for alcohol, illicit drug use or opioids
  3. Primary diagnosis of chronic low back pain due to neuropathic pain
  4. History of back surgery or plan for back surgery
  5. Use of opioids within 2 weeks of the first visit and during the study
  6. Previous ineffective use of lidocaine patches
  7. Morbid obesity
  8. Moderate or severe depression
  9. An open skin lesion within the painful area where patches will be applied
  10. Patients with active or resolved back pain litigation or receiving disability payments due to chronic low back pain
  11. Pregnant or breastfeeding females
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Bupivacaine TTS

    Drug: Bupivacaine TTS (Bupivacaine Patch)

  • Placebo comparator
    Placebo patch

    Drug: Placebo patch

Interventions

  • Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.

  • DrugPlacebo patch

    Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to 12 weeks in pain in the last 24 hours (daily scores averaged over 14 days)

    Time frame: baseline to 12 weeks after baseline

Secondary outcomes

  1. Subjects achieving 20% pain relief at 12 weeks compared to baseline

    Time frame: baseline to 12 weeks after baseline

  2. Subjects 'much improved' or 'very much improved' at 12 weeks

    Time frame: 12 weeks after baseline

07

Study locations

21 sites
  • Tempe, Arizona 85283, United States
  • La Mesa, California 91942, United States
  • Torrance, California 90502, United States
  • Fort Lauderdale, Florida 33306, United States
  • Gainesville, Florida 32605, United States
  • Longwood, Florida 32779, United States
  • West Palm Beach, Florida 33409, United States
  • Marietta, Georgia 30060, United States
  • Newnan, Georgia 30265, United States
  • Springfield, Massachusetts 01103, United States
  • Saint Louis, Missouri 63141, United States
  • New York, New York 10004, United States
  • Winston-Salem, North Carolina 27103, United States
  • Oklahoma City, Oklahoma 73109, United States
  • Allentown, Pennsylvania 18103, United States
  • Altoona, Pennsylvania 16602, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Austin, Texas 78756, United States
  • Dallas, Texas 75231, United States
  • Houston, Texas 77074, United States
  • Richmond, Virginia 23294, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2010
First posted
Mar 31, 2010
Start
Mar 2010
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results delay requested
Aug 16, 2011
Last update
Jun 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01096966
Lead sponsor
Durect
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 31, 2010
Start date
Mar 2010
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Jun 15, 2022

Study contacts

Paul Meisner, PharmD
study director · King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion